|
DC vaccine
|
|
Antwerp University Hospital
|
WT1 mRNA (i.d.)
|
Myeloid leukemia, multiple myeloma
|
NCT00965224 (II, randomized)
|
Standard-of-care
|
2009
|
Unknown [27]
|
|
AML
|
NCT01686334 (II, randomized)
|
Conventional chemotherapy
|
2012
|
Recruiting
|
|
GBM
|
NCT02649582 (I/II)
|
Temozolomide, temozolomide-based chemoradiation
|
2015
|
Recruiting
|
|
Malignant pleural mesothelioma
|
NCT02649829 (I/II)
|
Conventional chemotherapy
|
2017
|
Recruiting
|
|
Argos Therapeutics
|
Total tumor mRNA and CD40L mRNA (i.d.)
|
RCC
|
NCT00678119 (II, single arm)
|
Standard-of-care (sunitinib)
|
2008
|
Completed [28]
|
|
NCT01582672 (III, randomized)
|
2012
|
Terminated (Lack of effiacy) [29, 30]
|
|
Asterias Biotherapeutics, Inc.
|
hTERT mRNA with a LAMP-1 targeting sequence (i.d.)
|
AML (complete remission)
|
NCT00510133 (II, single arm)
|
None
|
2007
|
Completed [31]
|
|
Baylor College of Medicine
|
Tumor mRNA and tumor lysate (i.d.)
|
Pancreatic cancer
|
NCT04157127 (I)
|
Adjuvant to chemotherapy
|
2020
|
Recruiting
|
|
Duke University
|
LAMP-fused HCMV pp65 mRNA (i.d.) and td
|
Malignant neoplasms of brain
|
NCT00639639 (I)
|
None
|
2006
|
Active, not recruiting [32]
|
|
NCT02366728 (II, randomized)
|
Temozolomide, basiliximab (antagonistic anti-CD25)
|
2015
|
Active, not recruiting [33]
|
|
Glioblastoma
|
NCT03688178 (II, randomized)
|
Temozolomide, varlilumab (agonistic anti-CD27)
|
2020
|
Recruiting
|
|
LAMP-fused HCMV pp65 mRNA, GM-CSF (i.d.) and td
|
Malignant neoplasms of brain
|
NCT03615404 (I)
|
None
|
2018
|
Active, not recruiting
|
|
Glioblastoma
|
NCT03927222 (II, single arm)
|
Temozolomide
|
2019
|
Recruiting
|
|
Guangdong 999 Brain Hospital
|
Tumor mRNA
|
Brain cancer, neoplasm metastasis
|
NCT02808416 (I)
|
None
|
2016
|
Active, not recruiting
|
|
Recurrent glioblastoma
|
NCT02808364 (I)
|
None
|
2016
|
Active, not recruiting
|
|
Glioblastoma TAA mRNA (i.d. and i.v.)
|
Glioblastoma
|
NCT02709616 (I)
|
Conventional chemo- and radiotherapy
|
2016
|
Active, not recruiting
|
|
Hasumi International Research Foundation
|
IKKb-matured DCs with tumor mRNA, TAA mRNA (gp100, tyrosinase, PRAME, MAGE-A3, IDO) and neoAg mRNA (GNAQ/GNA11Q209 or R183) (i.v.)
|
Uveal metastatic melanoma
|
NCT04335890 (I)
|
None
|
2020
|
Recruiting
|
|
Herlev Hospital
|
PSA, PAP, survivin, hTERT mRNA (i.d.)
|
Metastatic prostate cancer
|
NCT01446731 (II, randomized)
|
Docetaxel
|
2011
|
Completed [34]
|
|
Immunomic Therapeutics, Inc.
|
HCMV pp65-shLAMP or pp65-flLAMP, GM-CSF and td (both)
|
GBM, glioblastoma, malignant glioma, astrocytoma
|
NCT02465268 (II, randomized)
|
Temozolomide
|
2016
|
Recruiting
|
|
Memorial Sloan Kettering Cancer Center
|
Langerhans-type DCs with Trp2 mRNA
|
Melanoma
|
NCT01456104 (I)
|
None
|
2011
|
Active, not recruiting
|
|
Langerhans-type DCs with CT7, MAGE-A3, WT1 mRNA
|
Multiple myeloma
|
NCT01995708 (I)
|
Standard-of-care
|
2014
|
Active, not recruiting
|
|
Oslo University Hospital
|
Tumor mRNA and hTERT, survivin TAA mRNA
|
Prostate cancer
|
NCT01197625 (I/II)
|
None
|
2010
|
Active, not recruiting
|
|
Radboud University
|
Tyrosinase, gp100 mRNA (i.d. and i.v.)
|
Melanoma
|
NCT02285413 (II, randomized)
|
Cisplatin
|
2011
|
Completed [35]
|
|
University Hospital Erlangen
|
Tumor mRNA
|
Uveal melanoma
|
NCT01983748 (III, randomized)
|
None
|
2014
|
Recruiting
|
|
University of Campinas
|
WT1 mRNA
|
Myelodysplastic syndromes, AML
|
NCT03083054 (I/II)
|
None
|
2016
|
Active, not recruiting
|
|
University of Florida
|
Total tumor mRNA and ex vivo expanded lymphocytes (i.v. and i.d.)
|
Medulloblastoma, neuroectodermal tumor
|
NCT01326104 (I, II)
|
None
|
2010
|
Active, not recruiting [36]
|
|
Total tumor mRNA, ex vivo expanded lymphocytes, GM-CSF and td
|
Diffuse intrinsic pontine glioma, Brain stem glioma
|
NCT03396575 (I)
|
Cyclophosphamide + fludarabine lymphodepleting conditioning or temozolomide
|
2018
|
Recruiting
|
|
Universitair Ziekenhuis Brussel, Bart Nens
|
MAGE-A3, MAGE-C2, tyrosinase and gp100 mRNA, co-electroporated with TriMix (CD70, CD40L, caTLR4) mRNA
|
Melanoma
|
NCT01302496 (II, single arm)
|
Ipilimumab (antagonistic anti-CTLA-4)
|
2011
|
Completed [37,38,39]
|
|
Melanoma
|
NCT01676779 (II, randomized)
|
None
|
2012
|
Completed [39]
|
|
Direct injection of mRNA
|
|
BioNTech SE
|
RNA-LPX with NY-ESO-1, MAGE-A3, tyrosinase and TPTE (i.v.)
|
Advanced melanoma
|
NCT02410733 (I)
|
None
|
2015
|
Active, not recruiting [40, 41]
|
|
RNA-LPX with TNBC TAAs, p53 and neoAgs (warehouse) (i.v.)
|
TNBC
|
NCT02316457 (I)
|
None
|
2016
|
Active, not recruiting
|
|
RNA-LPX with ovarian TAAs (i.v.)
|
Ovarian cancer
|
NCT04163094 (I)
|
Carboplatin and paclitaxel
|
2019
|
Recruiting
|
|
RNA-LPX with prostate TAAs (i.v.)
|
Prostate cancer
|
NCT04382898 (I/II)
|
Cemiplimab (antagonistic anti-PD-1) and/or goserelin acetate
|
2019
|
Recruiting
|
|
RNA-LPX with HPV16 antigens (i.v.)
|
HPV16+ and PD-L1+ HNSCC
|
NCT04534205 (II, randomized)
|
Pembrolizumab (antagonistic anti-PD-1)
|
2020
|
Not yet recruiting
|
|
RNA-LPX with NY-ESO-1, MAGE-A3, tyrosinase and TPTE (i.v.)
|
Melanoma
|
NCT04526899 (II, randomized)
|
Cemiplimab
|
2020
|
Not yet recruiting
|
|
RNA-LPX with CLDN6 (i.v.)
|
Solid tumors
|
NCT04503278 (I/II)
|
CLDN6-specific CAR-T cells
|
2020
|
Recruiting
|
|
Genentech Inc., BioNTech SE
|
RNA-LPX with tumor neoAgs (i.v.)
|
Different solid cancers
|
NCT03289962 (I)
|
Atezolizumab (antagonistic anti-PD-L1)
|
2017
|
Recruiting
|
|
Melanoma
|
NCT03815058 (II, randomized)
|
Pembrolizumab
|
2019
|
Recruiting
|
|
Changhai Hospital; Stemirna Therapeutics
|
mRNA encoding neoAg (s.c.)
|
Esophageal squamous carcinoma, gastric-, pancreatic- and colorectal adenocarcinoma
|
NCT03468244 (NA)
|
None
|
2018
|
Recruiting
|
|
CureVac AG
|
Protamine-formulated mRNA (RNActive) PSA, PSMA, PSCA, STEAP1, PAP and MUC1 (i.d.)
|
Prostate cancer
|
NCT01817738 (I/II, randomized)
|
None
|
2012
|
Terminated [42,43,44]
|
|
NCT02140138 (II, randomized)
|
Radical prostatectomy
|
2014
|
Terminated (after enrollment of 35/36 patients)
|
|
eTheRNA
|
mRNA encoding tyrosinase, gp100, MAGE-A3, MAGE-C2, and PRAME and TriMix (CD40L, CD70 and caTLR4) mRNA (i.n.)
|
Melanoma
|
NCT03394937 (I)
|
None
|
2018
|
Recruiting [45]
|
|
Ludwig Institute for Cancer Research, CureVac AG, Böhringer Ingelheim
|
RNActive encoding NY-ESO-1, MAGE-C1, MAGE-C2, TPBG, survivin, MUC1 (i.d.)
|
Meatastatic NSCLC
|
NCT03164772 (I/II)
|
Durvalumab (antagonistic anti-PD-L1), Tremelimumab (antagonistic anti-CTLA-4)
|
2017
|
Recruiting
|
|
Merck Sharp & Dohme Corp.
|
LNP-formulated mRNA encoding different KRAS mutations (i.m.)
|
KRAS-mutant NSCLC, colorectal cancer, pancreatic adenocarcinoma
|
NCT03948763 (I)
|
Pembrolizumab
|
2019
|
Recruiting
|
|
ModernaTX Inc., Merck Sharp & Dohme Corp.
|
Lipid-formulated mRNA encoding neoAg (i.m.)
|
Solid tumors
|
NCT03313778 (I)
|
Pembrolizumab
|
2017
|
Recruiting [46]
|
|
Melanoma
|
NCT03897881 (II, randomized)
|
Pembrolizumab
|
2019
|
Recruiting
|
|
University of Florida
|
Lipid-formulated mRNA with tumor and LAMP-fused HCMV pp65 TAA mRNA (i.v.)
|
Adult glioblastoma
|
NCT04573140 (I)
|
None
|
2020
|
Not yet recruiting
|
